ADT 1004
Alternative Names: ADT-1004Latest Information Update: 22 Jun 2024
At a glance
- Originator ADT Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024 2024)
- 14 Apr 2023 Preclinical trials in Pancreatic cancer in USA (PO)
- 14 Apr 2023 Pharmacodynamics, pharmacokinetic and adverse events data from a preclinical study in pancreatic cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)